Nautilus enters new $125M ATM sales agreement with TD Cowen; terminates prior unused agreement

Nautilus Biotechnology, Inc.

Entered ATM sales agreement with TD Cowen to sell up to $125M of common stock, with commission up to 3% of gross proceeds.
Prior ATM agreement dated Feb 28, 2024 mutually terminated; no shares had been sold under it.
Sales will occur via Rule 415 at-the-market offering under new S-3 shelf registration statement filed Sept 11, 2026.
Company not obligated to sell any shares and may suspend sales at any time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.